COMMUNIQUÉS West-GlobeNewswire

-
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
22/05/2024 -
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
22/05/2024 -
BrightSpring Health Services, Inc. to Participate in Three Upcoming Investor Conferences
22/05/2024 -
Nyxoah Announces Proposed Offering of Ordinary Shares
22/05/2024 -
Nyxoah Annonce une Proposition d'Offre d'Actions Ordinaires
22/05/2024 -
Cytokinetics Announces Proposed Public Offering of Common Stock
22/05/2024 -
Standard BioTools to Participate in Upcoming Investor Conferences
22/05/2024 -
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
22/05/2024 -
Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024
22/05/2024 -
Inventiva annonce deux présentations scientifiques lors de l’EASL International Liver Congress™ 2024
22/05/2024 -
Media Conference - Update: Fightback to Save Durham Hospital Ratcheting Up
22/05/2024 -
Bahrain Oncology Centre Amongst the First in the World to Offer Ground-breaking Sickle Cell and Transfusion Dependent Thalassemia Gene Therapy
22/05/2024 -
Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
22/05/2024 -
ONWARD® Medical organise une téléconférence pour partager les détails relatifs à son étude clinique Up-LIFT et à sa publication dans la revue Nature Medicine
22/05/2024 -
SOHM, Inc., Targets Revolutionary New ABBIE Genome Editing Kits for Q3, 2024
22/05/2024 -
GENFIT: May 22, 2024 Combined Shareholders Meeting Results
22/05/2024 -
GENFIT : Résultats de l’Assemblée Générale Mixte du 22 mai 2024
22/05/2024 -
Syapse Expands Oncology Real-World Data Offerings with Introduction of Syapse Cohorts: Essentials
22/05/2024 -
Guerbet : NUCLIDIUM et Guerbet concluent un partenariat stratégique pour soutenir le développement de la radiothéranostique ciblée basée sur des radio-isotopes de cuivre.
22/05/2024
Pages